The group is a formulation science group and recognized as a leader in nasal drug delivery technology. formulation science is a systematic approach to drug development using biophysics, physical chemistry and pharmacology to maximize therapeutic efficacy and safety. the technology is essential in designing an optimized, customizable dosage form and in delivering difficult protein and large molecule drugs that can currently only be delivered by injection. august 2001, the group licensed its proprietary morphine technology to g. pohl boskamp gmbh & co. in order to develop, manufacture, market and sell its intranasal morphine products in europe. february 1, 2002, the group entered into a licensing agreement with pharmacia & upjohn company. license fee, royalty and research income accounted for 62% of 2001 revenues and pharmaceuticals, 38%.